ASH Clinical News ACN_4.5_FULL_ISSUE_DIGITAL - Page 8

ASH Participates in Roundtable Discussion With Senator Booker
Submit Your Nomination to Become an ASH Choosing Wisely Champion

ASH Directions

UP FRONT

Get Ready for the ASH Summit on Emerging Immunotherapies

The first-of-its-kind ASH Summit on Emerging Immunotherapies for Hematologic Diseases will take place July 12 to 13 in Washington , DC . Through breakout and didactic sessions , attendees will examine pre-clinical and clinical factors influencing the effective development , regulation , and implementation of immunotherapies for both malignant and non-malignant hematologic diseases . The interactive program aims to foster strategic collaborations among researchers , clinicians , regulators , industry scientists , and patient advocates . For more information and to register , visit hematology . org / meetings .

ASH Participates in Roundtable Discussion With Senator Booker

On February 28 , Sens . Tim Scott ( R-SC ) and Cory Booker ( D-NJ ) introduced the Sickle Cell Disease Surveillance , Prevention , and Treatment Act of 2018 ( see page 12 to learn more about the legislation ). To mark its introduction , Sen . Booker hosted a roundtable discussion in collaboration with the American Society of Hematology ( ASH ). ASH Secretary Robert Brodsky , MD , joined two patients with sickle cell disease
( SCD ), a parent of a patient with SCD , and Biree Andemariam , MD , chief medical officer of the Sickle Cell Disease Association of America , to discuss upcoming research opportunities , share stories , and explain why the legislation is needed . Visit Sen . Booker ’ s Facebook page ( facebook . com / corybooker ) to access a recorded version of the event .
Blood Review Series on “ Strategies to Improve GVL Effects ”
The latest Blood review series explores developments in treatments to enhance graft-versus-leukemia effects in allogeneic hematopoietic cell transplantation , including cellular therapies , antibody-based treatments , and drugbased approaches using tyrosine kinase inhibitors and checkpoint blockade . The review series articles include :
Posttransplant chimeric antigen receptor therapy Melody Smith , MD ; Johannes Zakrzewski , MD ; Scott James , MD ; and Michel Sadelain , MD , PhD
Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation Sarah Cooley , MD ; Peter Parham , PhD ; and Jeffrey S . Miller , MD
The potential role of γδ T cells after allogeneic HCT for leukemia Rupert Handgretinger , MD , and Karin Schilbach , PhD
Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation Robert J . Soiffer , MD ; Matthew S . Davids , MD ; and Yi-Bin Chen , MD
To read the entire series and watch a video highlight featuring Blood Associate Editor Robert Zeiser , MD , visit hematology . org / GVLreview .

The Hematologist App

ASH Secretary Robert Brodsky , MD , ( at left ), discusses the Sickle Cell Disease Surveillance , Prevention , and Treatment Act with SCD patient advocate Dominique Goodson and Sen . Cory Booker .

Submit Your Nomination to Become an ASH Choosing Wisely Champion

In partnership with the American Board of Internal Medicine Foundation , ASH recognizes efforts of practitioners who are working to eliminate costly and potentially harmful overuse of common tests and procedures . The application cycle for the 2018 ASH Choosing Wisely Champions is now open . This year ’ s three Champions will present their strategies at the 60th ASH Annual Meeting and Exposition in San Diego . Clinicians , researchers , or trainees at all levels in both academic and community settings are encouraged to apply by June 1 .
Visit hematology . org / ChoosingWisely for more information .
Available Now : The Hematologist App
Readers of The Hematologist can now enjoy great content on the go , and even offline ! Download The Hematologist app and save your favorite articles to your smartphone or tablet . Take notes , listen to podcasts , and more , with one convenient app – available at hematology . org / thehematologist / app . ●
6 ASH Clinical News April 2018
UP FRONT ASH Directions Get Ready for the ASH Summit on Emerging Immunotherapies The first-of-its-kind ASH Summit on Emerging Immunotherapies for Hematologic Diseases will take place July 12 to 13 in Washington, DC. Through breakout and didactic sessions, attendees will examine pre-clinical and clinical factors influencing the effective development, regulation, and implementation of immunotherapies for both malignant and non-malignant hematologic diseases. The interactive program aims to foster strategic collaborations among researchers, clinicians, regulators, industry scientists, and patient advocates. For more information and to register, visit hematology.org/meetings. ASH Participates in Roundtable Discussion With Senator Booker On February 28, Sens. Tim Scott (R-SC) and Cory Booker (D-NJ) introduced the Sickle Cell Disease Surveillance, Prevention, and Treatment Act of 2018 (see page 12 to learn more about the legislation). To mark its introduction, Sen. Booker hosted a roundtable discussion in col- laboration with the American Society of Hema- tology (ASH). ASH Secretary Robert Brodsky, MD, joined two patients with sickle cell disease (SCD), a parent of a patient with SCD, and Biree Andemariam, MD, chief medical officer of the Sickle Cell Disease Association of Ameri- ca, to discuss upcoming research opportunities, share stories, and explain why the legislation is needed. Visit Sen. Booker’s Facebook page (facebook.com/corybooker) to access a recorded version of the event. Blood Review Series on “Strategies to Improve GVL Effects” The latest Blood review series explores developments in treatments to enhance graft-versus-leukemia effects in allogeneic hematopoietic cell transplantation, including cellular therapies, antibody-based treatments, and drug- based approaches using tyrosine kinase inhibitors and checkpoint blockade. The review series articles include: Posttransplant chimeric antigen receptor therapy Melody Smith, MD; Johannes Zakrzewski, MD; Scott James, MD; and Michel Sadelain, MD, PhD Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation Sarah Cooley, MD; Peter Parham, PhD; and Jeffrey S. Miller, MD The potential role of γδ T cells after allogeneic HCT for leukemia Rupert Handgretinger, MD, and Karin Schilbach, PhD Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation Robert J. Soiffer, MD; Matthew S. Davids, MD; and Yi-Bin Chen, MD To read the entire series and watch a video highlight featuring Blood Associate Editor Robert Zeiser, MD, visit hematology.org/GVLreview. Available Now: The Hematologist App ASH Secretary Robert Brodsky, MD, (at left), discusses the Sickle Cell Disease Surveillance, Prevention, and Treatment Act with SCD patient advocate Dominique Goodson and Sen. Cory Booker. Submit Your Nomination to Become an ASH Choosing Wisely Champion In partnership with the American Board of Inter- nal Medicine Foundation, ASH recognizes efforts of practitioners who are working to eliminate costly and potentially harmful overuse of com- mon tests and procedures. The application cycle for the 2018 ASH Choosing Wisely Champions is now open. This year’s three Champions will present their strategies at the 60th ASH Annual Meeting and ^][ۈ[[YYˈ[KBX[\X\\܈Z[Y\][][[XY[ZX[[][]H][\H[\YY\HH[H K\][X]Kܙ[\[H܈[ܙB[ܛX][ۋXY\وH[X]\[]ܙX]۝[ۈH[][ٙ[HXH[\S܈[YX\ۙH܈X] H\X\[]H[\]ܚ]\ZH\[XZHYY\[\܈]Y[ˈ]YX][ۜ[H[HB\]Y\ۈ\]\X\XYH]Z[XK[H[[\H[][۝[][\XYY\XHH\Y]HوX[YYXH܈[XZ[\XHHH\ ]Z[XHΈH[X]\\H[X]\\\ۙH[ܙH^H[H۝[ܘYY\XX[H܈[X]\H[X]\˂XY\›وH[X]\[[HܙX]۝[ۈH[][ٙ[HHۛYB܈[ܙH[ܛX][ۋ\]˚[X]KܙZ[X]\ \ [X]\\[]H[\]ܚ]H\X\[\X\ۙH܈X] ZH\\[\[[ܙK]ۙH۝[Y[\8$]Z[XH][X]KܙZ[X]\ \ 8T[X]\\YPӈ[YH [ BT[X[]ŒN ΍ B\[ N